Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $75
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $75.
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $75.